Announcements
- Chemomab Therapeutics to Participate in Upcoming Scientific Conferences
- Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
- Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
- Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference
- Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update
- Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
- Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
- Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
More ▼
Key statistics
On Friday, Chemomab Therapeutics Ltd (2QV0:STU) closed at 0.91, 133.33% above the 52 week low of 0.39 set on Dec 13, 2023.
52-week range
Open | 0.96 |
---|---|
High | 0.96 |
Low | 0.91 |
Bid | 0.87 |
Offer | 1.02 |
Previous close | 0.915 |
Average volume | 60.00 |
---|---|
Shares outstanding | 14.22m |
Free float | 13.54m |
P/E (TTM) | -- |
Market cap | 15.21m USD |
EPS (TTM) | -26.80 USD |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼